RIBOMIC Announces Preliminary Topline Data From Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration
TOKYO--(BUSINESS WIRE)--RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced the topline data from the Phase 2 TOFU study of RBM-007 in patients with Wet Age-Related Macular Degeneration (wAMD). TOFU study is a double-masked, randomized, active-controlled Phase 2 trial (n=86) evaluating the efficacy and safety of RBM-007 monotherapy and RBM-007 in combination with Eylea® compared to Eylea® monotherapy in patients with wAMD who